Impact of HbA1c reduction on major kidney outcomes in type 2 diabetes with poor glycemic control and advanced CKD

Aims: In subjects with type 2 diabetes (DM), poor glycemic control, and advanced chronic kidney disease (CKD), the kidney beneft of the reduction of glycated hemoglobin (HbA1c) is not well established. Methods: In a retrospective cohort, we included patients with DM, CKD grade 3b-5, and HbA1c > 9...

Full description

Autores:

Navarro Blackaller, Guillermo
Benitez-Renteria, A. S.
Hernández-Morales, K.
Rico-Fontalvo, Jorge
Daza-Arnedo, R.
Gómez-Ramírez, G. G.
Camacho-Guerrero, J. R.
Pérez-Venegas, M. A.
Carmona-Morales, J.
Oseguera-González, A. N.
Murguía Soto, César
Chávez-Alonso, G.
García-Peña, F.
Barrera-Torres, C. J.
Orozco-Chan, E.
Arredondo-Dubois, M.
Martínez Gallardo González, Alejandro
Gómez-Fregoso, J. A.
Rodríguez-García, F. G.
Luquin-Arellano, V. H.
Abundis-Mora, G.
Alcantar-Vallin, L.
Medina-González, R.
García-García, G.
Chávez-Iñiguez, Jonathan S.

Tipo de recurso:

Fecha de publicación:

2025

Institución:

Universidad Simón Bolívar

Repositorio:

Repositorio Digital USB

Idioma:

eng

OAI Identifier:

oai:bonga.unisimon.edu.co:20.500.12442/16553

Acceso en línea:

https://hdl.handle.net/20.500.12442/16553
https://doi.org/10.1155/ije/9919963
https://onlinelibrary.wiley.com/journal/1573

Palabra clave:

Chronic kidney disease
Diabetes
Kidney replacement therapy
Major adverse kidney events
Mortality

Rights

openAccess

License

Attribution-NonCommercial-NoDerivatives 4.0 International